权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of technetium-99m and rhenium-186 labeled monoclonal antibodies for imaging and therapy.

开发用于成像和治疗的 technetium-99m 和铼-186 标记的单克隆抗体。

基本信息

批准号：
05454299
负责人：
ENDO Keigo
金额：
$ 3.33万
依托单位：
Gunma University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (B)
财政年份：
1993
资助国家：
日本
起止时间：
1993 至 1994
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-05454299/
关键词：
Radionuclides Diagnostic Imaging Radionuclide Therapy Monoclonal antibody Technetium-99m Rhenium-186 レニウム-186

项目摘要

This study was performed to develop new imaging and therapeutic methods using technetium-99m and rhenium-186 labeled monoclonal antibodies.Technetium-99m labeled antibodies against carcinoembryonic antigen (CEA) were intravenously administered to patients with colorectal cancer, and its biodistribution and tumor uptake were examined in 12 patients. Eleven (92%) cases showed positive results with antibodies and tumor-to-normal tissue ratios obtained with SPECT correlated well with those obtained using surgical specimen. The highest tumor-to-normal tissue ratio reached more than 14 and there were several cases who seemed to be good candidates for radioimmunotherapy. Techetium-99m labeled anti-CA125 antibodies also accumulated in the ovarian cancer tissues in 3 out of 7 cases and needs further investigation.The biggest problem inherent to clinical use of monoclonal antibodies is the generation of human anti-murine antibody (HAMA) in the serum of patients who received monoclonal antibodies. Rapid progress of gene technology allowed us to produced humanized monoclonal antibodies. Technetium-99m labeled humanized antibodies were safely administered to patients and no HAMA were detectable in their serum. Clinical use of humanized antibodies seemed promising not only in the immunoscintigraphy but also in the therapy of cancer.

本研究旨在利用锝-99m和铼-186标记的单克隆抗体开发新的成像和治疗方法。将锝-99m标记的癌胚抗原（CEA）抗体静脉注射给结直肠癌患者，并在12名患者中检查其生物分布和肿瘤摄取。 11 例 (92%) 病例显示出抗体阳性结果，SPECT 获得的肿瘤与正常组织的比率与手术标本获得的结果具有良好的相关性。肿瘤与正常组织的比率最高达到14以上，并且有几个病例似乎适合放射免疫治疗。 Techetium-99m标记的抗CA125抗体在7例中的3例中也在卵巢癌组织中积累，需要进一步研究。单克隆抗体临床使用固有的最大问题是接受单克隆抗体的患者血清中产生人抗鼠抗体（HAMA）。基因技术的快速进步使我们能够生产人源化单克隆抗体。 Technetium-99m 标记的人源化抗体被安全地施用于患者，并且在他们的血清中未检测到 HAMA。人源化抗体的临床应用不仅在免疫闪烁扫描方面而且在癌症治疗方面似乎都有希望。